Company Page
Most Recent Insiders Activity
| Transaction Date | Company Name | Insider Name (Title) | Activity | Stock | Acquired or Disposed | Shares | Price range | Amount |
|---|---|---|---|---|---|---|---|---|
| 2024-03-27 | Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC
(CHIEF FINANCIAL OFFICER) |
P | Common Stock | A | 2000 | $24.80 - $24.80 | $49,600 |
| 2024-03-25 | Mirum Pharmaceuticals, Inc. | Radovich Peter
(PRESIDENT AND COO) |
S | Common Stock | D | 4303 | $25.80 - $25.80 | $111,017 |
| 2023-01-09 | Mirum Pharmaceuticals, Inc. | Radovich Peter
(PRESIDENT AND COO) |
S | Common Stock | D | 1379 | $20.62 - $20.62 | $28,438 |
| 2023-01-09 | Mirum Pharmaceuticals, Inc. | Vig Pamela
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 1379 | $20.62 - $20.62 | $28,438 |
| 2023-01-09 | Mirum Pharmaceuticals, Inc. | Longpre Lara
(CHIEF DEVELOPMENT OFFICER) |
S | Common Stock | D | 1003 | $20.62 - $20.62 | $20,684 |
| 2019-09-10 | Mirum Pharmaceuticals, Inc. | Longpre Lara
(CHIEF DEVELOPMENT OFFICER) |
P | Common Stock | A | 965 | $10.64 - $10.64 | $10,267 |
| 2023-01-09 | Mirum Pharmaceuticals, Inc. | Peetz Christopher
(CHIEF EXECUTIVE OFFICER) |
S | Common Stock | D | 5159 | $20.62 - $20.62 | $106,390 |
| 2024-03-18 | Mirum Pharmaceuticals, Inc. | BJERKHOLT ERIC
(CHIEF FINANCIAL OFFICER) |
P | Common Stock | A | 2000 | $25.80 - $25.80 | $51,600 |
| 2024-02-02 | Mirum Pharmaceuticals, Inc. | Vig Pamela
(CHIEF SCIENTIFIC OFFICER) |
S | Common Stock | D | 1214 | $26.19 - $26.19 | $31,796 |
| 2024-02-02 | Mirum Pharmaceuticals, Inc. | Longpre Lara
(CHIEF DEVELOPMENT OFFICER) |
S | Common Stock | D | 847 | $26.19 - $26.19 | $22,184 |
| 2024-02-02 | Mirum Pharmaceuticals, Inc. | Radovich Peter
(PRESIDENT AND COO) |
S | Common Stock | D | 1790 | $26.19 - $26.19 | $46,883 |
| 2024-02-02 | Mirum Pharmaceuticals, Inc. | Peetz Christopher
(CHIEF EXECUTIVE OFFICER) |
S | Common Stock | D | 6013 | $26.19 - $26.19 | $157,491 |
| 2024-02-02 | Mirum Pharmaceuticals, Inc. | Howe Jolanda
(SVP, GLOBAL CONTROLLER) |
S | Common Stock | D | 735 | $26.19 - $26.19 | $19,250 |
| 2024-01-08 | Mirum Pharmaceuticals, Inc. | Radovich Peter
(CHIEF OPERATING OFFICER) |
S | Common Stock | D | 1408 | $28.03 - $28.03 | $39,472 |
| 2024-01-08 | Mirum Pharmaceuticals, Inc. | Longpre Lara
(CHIEF DEVELOPMENT OFFICER) |
S | Common Stock | D | 1019 | $28.04 - $28.04 | $28,567 |
| 2024-01-08 | Mirum Pharmaceuticals, Inc. | Vig Pamela
(HEAD OF RESEARCH & DEVELOPMENT) |
S | Common Stock | D | 1408 | $28.03 - $28.03 | $39,472 |
| 2024-01-08 | Mirum Pharmaceuticals, Inc. | Peetz Christopher
(PRESIDENT AND CEO) |
S | Common Stock | D | 5209 | $28.03 - $28.03 | $146,033 |
| 2024-01-08 | Mirum Pharmaceuticals, Inc. | Howe Jolanda
(SVP, GLOBAL CONTROLLER) |
S | Common Stock | D | 528 | $28.04 - $28.04 | $14,802 |
| 2023-12-05 | Mirum Pharmaceuticals, Inc. | Howe Jolanda
(SVP, Global Controller) |
S | Common Stock | D | 2500 | $32.40 - $32.40 | $81,000 |
| 2023-12-05 | Mirum Pharmaceuticals, Inc. | Howe Jolanda
(SVP, Global Controller) |
M | Common Stock | A | 2500 | $2.94 - $2.94 | $7,350 |
| 2023-11-10 | Mirum Pharmaceuticals, Inc. | Vig Pamela
(Head of Research & Development) |
A | Common Stock | A | 527 | $22.29 - $22.29 | $11,745 |
| 2023-11-10 | Mirum Pharmaceuticals, Inc. | Longpre Lara
(Chief Development Officer) |
A | Common Stock | A | 434 | $22.29 - $22.29 | $9,672 |
| 2023-11-10 | Mirum Pharmaceuticals, Inc. | Radovich Peter
(Chief Operating Officer) |
A | Common Stock | A | 218 | $22.29 - $22.29 | $4,858 |
Activity types
| A | Grant, award or other acquisition |
| C | Conversion of Derivative or Security |
| D | Disposition to the issuer of issuer equity securities |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability |
| G | Bona fide Gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary Transaction |
| J | Other acquisition or disposition |
| K | Transaction in equity swap or instrument with similar characteristics |
| L | Small Acquisition |
| M | Exercise or conversion of derivative security |
| O | Exercise of out-of-the-money derivative security |
| P | Open Market Purchase |
| S | Open Market Sale |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| V | Transaction Voluntarily Reported |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |